I'll research PFE before writing the preview. Let me gather recent earnings, filings, news, and analyst context.Let me read the latest earnings materials and guidance call, and pull more context.Let me pull recent news context and stock price performance.# Pfizer (PFE) — Q2 2026 Earnings Preview
The Street expects Q2 EPS of 68¢ and revenue of $14.4B, down about 1.5% year-over-year. This would represent a modest sequential and year-over-year step down from Q1's strong print, largely reflecting the well-telegraphed erosion of the COVID franchise and select loss-of-exclusivity (LOE) headwinds.
Sentiment is cautious. Bears cite tepid revenue trends, patent risks, and a mixed pipeline track record, while bulls highlight the cheap valuation, elevated dividend, and pipeline opportunities bolstered through recent M&A. This is the classic PFE debate — a deep-value, high-yield defensive name in transition, where the story is less about the current quarter and more about the credibility of the post-2028 growth reacceleration.
Stock context: PFE is essentially flat year-to-date (~$25.0 vs. ~$25.2 to start 2026), meaningfully lagging the healthcare sector (XLV +~4%). The stock peaked near $28.5 in early April (on the Vyndamax settlement news) before sliding to a ~$23.7 trough in late June, and has since clawed back to ~$25. The dividend (43¢/quarter, ~$1.72 annualized) implies a yield near 7% — a central pillar of the bull case and the number one thing income investors will be watching for reassurance on.
Pfizer entered this print with momentum. In Q1 2026: - Revenue of $14.5B, +2% operationally (+5% reported), beating expectations. - Adjusted EPS of $0.75 (reported $0.47), also a beat. - Ex-COVID revenue grew ~7% operationally; launched and acquired products grew 22% operationally to $3.1B. - Adjusted operating margin was a robust 38%, above pre-pandemic levels.
Importantly, management reaffirmed (did not raise) full-year 2026 guidance despite the beat. CFO Dave Denton essentially said that absent COVID seasonality, they "probably would be raising guidance" — a hint that the underlying business is tracking ahead. Watch closely whether Q2 strength prompts a guidance raise or narrowing this time.
FY26 guidance to hold against: | Metric | Guidance | |---|---| | Revenue | $59.5B – $62.5B | | Adjusted SI&A | $12.5B – $13.5B | | Adjusted R&D | $10.5B – $11.5B | | Adjusted tax rate | ~15.0% | | Adjusted EPS | $2.80 – $3.00 |
Note: guidance assumes no share repurchases and a ~$1.5B unfavorable revenue impact from generic/biosimilar competition.
This is the biggest swing factor for the optical revenue miss/beat. In Q1, Comirnaty fell 59% and Paxlovid fell 63% operationally. Management has been explicit that the COVID franchise is back-half weighted to vaccination season, so Q2 COVID revenue should be seasonally minimal. Don't over-react to weak COVID numbers — focus on the ex-COVID growth rate (Q1: ~7% operationally). A clean beat requires the base business to keep compounding.
The single most important structural metric. This basket (Padcev, Nurtec, Elrexfio, Abrysvo, Vyndaqel family, Lorbrena, etc.) grew 22% operationally in Q1 and annualizes toward $12B+. Management frames these products as the direct offset to the ~$14–15B of LOE exposure through 2028. Look for: - Padcev (+39% op in Q1) momentum in first-line urothelial and the muscle-invasive bladder cancer (MIBC) launch — a PDUFA action date of August 17, 2026 for the all-comers perioperative expansion is a near-term catalyst. - Nurtec (+41% op) — still only ~40% of triptan writers have adopted an oral CGRP, leaving runway. - Vyndaqel/Vyndamax family (+4% op) — U.S. under net-price pressure from new payer contracts, offset by international demand.
In April, Pfizer settled with generic makers, extending U.S. Vyndamax patent protection to June 1, 2031 (from a prior ~2029 cliff). This effectively stabilizes a $6B+ franchise through mid-2031 and is the linchpin of management's raised confidence in a high-single-digit revenue CAGR for the 5 years starting 2029. Expect management to reiterate this framing and any updated cash flow/EPS implications.
Pfizer is positioning obesity as a future growth pillar via the Metsera acquisition, targeting a first approval in 2028 and 10 Phase 3 studies this year. Around the June ADA meeting, Pfizer planned to share detailed VESPER-3 data, plus VESPER-1 (open-label extension) and VESPER-2 (weekly danuglipron ± titration in T2D) data. Critically, amylin monotherapy data (24-week mono, 28-week combo) is expected in 2H 2026 — this is the most-watched catalyst and could move the stock more than the quarter itself. Listen for any updates on obesity pipeline execution, dosing/tolerability differentiation (differentiated monthly maintenance dosing ambition), and the international opportunity (e.g., China ecnoglutide launch).
Roughly half of 2026's key readouts/regulatory decisions come from oncology. Watch for updates on: - Sigvotatug vedotin (SV) — second-line non-squamous NSCLC readout expected mid-year (vs. docetaxel, powered for OS). - Mevrometostat (MEVPRO-1) — post-abiraterone prostate cancer readout in mid/2H 2026. - Recent Phase 3 wins already in hand: Elrexfio (MagnetisMM-5), Talzenna (TALAPRO-3), Braftovi (BREAKWATER), and atirmociclib Phase 2 in breast cancer.
Two items to monitor in commentary: - U.S. pricing / MFN: Pfizer joined TrumpRx.gov with 30+ discounted medicines as part of a Most-Favored-Nation agreement — watch for margin/revenue framing. - Section 232 pharma tariffs: Pfizer is negotiating a binding tariff agreement with the U.S. government tied to expanded domestic manufacturing investment; unresolved tariff exposure remains a risk factor.
This is unlikely to be a quarter where the headline numbers surprise dramatically — COVID seasonality makes a modest YoY revenue decline the base case, and management has a habit of holding guidance in the first half. The real signal is in three places: (1) the durability of the ~7% ex-COVID / +22% launched-and-acquired growth engine that must offset the LOE cliff; (2) any guidance raise/narrowing that confirms the Q1 beat wasn't a one-off; and (3) pipeline read-throughs, especially obesity (amylin data in 2H) and mid-year oncology readouts, which underpin the 2029+ high-single-digit CAGR thesis.
For a stock trading at a mid-single-digit forward multiple with a ~7% yield, the risk/reward hinges less on the 68¢ print and more on whether management can keep reinforcing the bridge from today's LOE-pressured business to a credible late-decade reacceleration — now anchored by the Vyndamax extension to 2031. Confirmation of dividend safety and any hint at buyback resumption would be the most likely positive catalysts; softer base-business trends or pipeline setbacks would be the key downside risks.
Note: Consensus figures and dividend/valuation math are drawn from available news and reported financials; verify against the latest sell-side models before the print.